(LN) will progress to renal damage [2] , partly as a result of the difficulty in recognizing the onset of the disease and relapses, early enough to establish a prompt treatment able to modify the course of the disease.
At present, renal biopsy remains the 'gold standard' to diagnose and provide direct assessment of the degree of kidney damage, but due to its invasive nature cannot be performed serially. Traditional serological biomarkers, such as anti-dsDNA antibodies and complement levels, and laboratory tests for kidney function have been proved unreliable [3, 4] . For this reason, in recent years, there has been a growing interest in finding a non-invasive 'surrogate marker' of lupus renal disease that could be used to predict the onset of the disease and to monitor its progression. Urinary biomarkers are attractive candidates [5, 6] since not only are they relatively easy to measure, but they specifically reflect the local pathophysiological changes.
Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 kDa protein belonging to the lipocalin superfamily that has been extensively studied in acute kidney injury . It is one of the most robustly expressed proteins in the kidney following ischaemic or nephrotoxic injury in both animal models and humans [7] [8] [9] . In adult and childhood-onset SLE, it has been found to be a significant predictor of disease activity and flare [10] [11] [12] [13] [14] [15] , whereas in patients with an existing renal disease it is a predictor of disease progression [16] [17] [18] . In addition, NGAL also seems to be involved in renoprotection, in view of its implication in the development and de-differentiation of tubular epithelia following ischemia-reperfusion, it may predict graft function recovery, and administered into animal models, can mitigate renal injury [19] [20] .
Therefore, we hypothesized that NGAL, besides being a biomarker of active and/or progressive disease, can also be a biomarker of recovery. The goal of our study is to investigate the association of NGAL with renal disease activity, response to therapy and progression to chronic kidney disease (CKD).
M AT E R I A L S A N D M E T H O D S
SLE patients from the Lupus Unit at Vall d'Hebron Hospital (Barcelona, Spain), fulfilling at least four of the American College of Rheumatology (ACR) revised classification criteria for SLE [21] , were enrolled. Patients with urinary tract infection, diabetes mellitus, pregnancy, malignancy, non-lupusrelated renal failure and those undergoing haemodialysis or with renal transplantation history were excluded. The study was approved by the local Ethics Committee and all patients gave written informed consent.
Disease activity was assessed by the SLE Disease Activity Index 2000 update (SLEDAI-2Ks; range 0-105) [22] . Renal activity was defined as the sum of the SLEDAI-2Ks accrued in the renal domain of the measure (rSLEDAIs; range 0-16). Extra-renal disease activity was calculated by subtracting the rSLEDAIs from the total SLEDAI score [SLEDAI-2K extrarenal score (eSLEDAIs); range 0-89]. Accumulated renal damage was assessed by the renal-related data of the SLICC/ ACR damage index (rSDI; range 0-47) [23] .
Renal biopsies were performed within 1 week of starting treatment, unless contraindicated. Renal-biopsy specimens were examined by a light and immunofluorescence microscopy, and the findings were categorized according to the International Society of Nephrology/Renal Pathology Society classification (2003) [24] and rated for activity and chronicity [25] .
Two different cross-sectional and prospective cohorts of patients were established to evaluate the association of NGAL levels with disease activity and its predictive value in clinical outcome, respectively.
Patients in the cross-sectional study were categorized into: (i) SLE patients with LN. Those in turn were subclassified into three groups according to the renal activity status at inclusion: patients with active LN (ALN), defined by a new rSLEDAI ≥8 or rSLEDAI = 4 when proteinuria was the only renal-related criterion, and/or by biopsy-proven active renal disease (n = 38), and those with a previously treated LN that at the inclusion time achieved a partial response (PR) (n = 56) or complete response (CR) (n = 29), defined by a urinary protein-to-creatinine ratio (Upro : Ucre ratio) between 0.2-2.0 and <0.2, respectively, with the presence of a normal sediment in those with CR [26] . (ii) SLE patients without history of renal involvement with an active disease (SLEDAIs ≥6) (n = 23) or with inactive SLE (SLEDAIs <4) (n = 39). A control group of healthy volunteers (n = 35) was also included.
For the prospective study, a new cohort of 45 consecutive patients with new onset biopsy-proven LN was established. Patients were followed-up monthly for the first 6 months and three-monthly afterwards. Renal flares were classified as nephritic or proteinuric. Nephritic flares were defined by ≥30% increase in serum creatinine [or, decrease in estimated glomerular filtration rate (eGFR) by ≥10%] and active urine sediment with increase in glomerular haematuria (≥10 red blood cells per high power field, irrespective of changes in proteinuria; proteinuric flares by reproducible doubling of the Upro : Ucre ratio >0.9 mg/mg after CR or reproducible doubling of the Upro : Ucre ratio to >1.8 mg/mg after PR [27] .
At each visit the SLEDAI-2Ks was recorded and laboratory tests were performed, including: full blood count, serum biochemistry, complement levels, anti-dsDNA antibody titres, complete urine analysis, 24-h proteinuria, Upro : Ucr ratio and the eGFR by using the Cockcroft-Gault equation [28] . All samples were obtained during the morning hours on the day of the clinic visit.
The LN disease course was categorized based on the change in disease activity at a reference time point, either due to the development of flare (time A) or achievement of CR following treatment (time B), and progression to CKD. The respective disease activity and response to treatment scores were compared between two time points: the time of the event (time A or B) and the time of the preceding visits (-A1, -A2 and -B1, -B2).
Urinary (uNGAL) and serum NGAL (sNGAL) measurements by the enzyme-linked immunosorbent assay (ELISA).
For each patient, fresh blood and urine samples were collected. Urine samples were centrifuged at 2500 g (4°C) for 30 min to remove cellular debris before storing. Urine and serum samples were frozen within 2 h after collection and
stored at −80°C until further analysis. NGAL levels were measured by ELISA using a commercially available kit (Bioporto, Denmark) following the manufacturer's instructions. Plates were read at 450 nm. All the measurements were made in duplicate. The lower limit of detection was 0.5-4 ng/mL. Undetectable values were assigned a value of 0.
Assay standardization uNGAL concentrations were normalized to urine-creatinine to correct for differences due to urine dilution in the same sample, with results being expressed as nanograms of uNGAL per milligram of urinary creatinine (ng/mg Cr). Fractional excretion (FE) indicators of NGAL (FE NGAL) were calculated using the formula: (urine/serum analyte concentration)/(urine/serum creatinine concentration) × 100. FE NGAL relative to the FE of total proteins (FE NGAL/FE protein) was calculated.
Statistical analysis
Cross-sectional study. Percentages and quartiles were used as descriptive statistics for categorical and continuous variables, respectively. Inferences on population mean values were done with 95% confidence intervals. Comparisons between groups were performed by means of the Chi-square test or Fisher's exact test for categorical and the Mann-Whitney U test for continuous values. Spearman's rank correlation coefficient was used to estimate the association between continuous variables. To perform multiple comparisons of various biochemical markers against the ALN group, a generalized linear model with a log link was fitted, and then Dunnett's test was applied in order to adjust the P-values. Areas under ROC curves were calculated and the cut-off points were determined according to Youden's index. Sensitivity, specificity and positive and negative predictive values, and their 95% confidence intervals, were also computed using generalized linear models with a logit link.
Longitudinal study. Descriptive, inferential and correlation statistics were estimated with the same methods as in the cross-sectional study. Within-patient comparisons at different time points were carried out with generalized estimating equations in order to account for the repeated measurements design. Kaplan-Meier and Cox proportional hazards methods were used to analyse the relationship between the markers and the time to kidney disease progression. Statistical analyses were done with PASW Statistics 17.0 (SPSS, Inc., 2009, Chicago, IL, USA) and SAS 9.1.3 (SAS Institute, Inc., Cary, NC, USA).
R E S U LT S
Baseline patient characteristics Patients' demographic characteristics, medication usage and laboratory measurements both in the cross-sectional and longitudinal studies are summarized in Tables 1 and 2 . In both cohorts, there was a female (87-89%) and biopsy-proven type IV GMN (78-79%) predominance. In the cross-sectional cohort, renal patients had significantly higher SLEDAI-2Ks and rSLEDAIs and were taking mycophenolate mofetil (MMF) (P = 0.0006) and angiotensin-blocking agents (P = 0.0184) more frequently, whereas hydroxychloroquine was more prevalent in non-renal patients (P = 0.0087). As expected, patients with LN had significantly higher anti-dsDNA antibodies titres, creatinine levels and Upro : Ucre ratios along with lower eGFRs. All patients in the longitudinal study received MMF as continuous induction-maintenance therapy.
NGAL levels in relation to disease activity NGAL and renal disease activity. SLE patients had significantly higher uNGAL levels than healthy controls 241.4-344.9) pg/mL, P = 0.846], a significant difference was found between patients with ALN and those with non-active SLE (P = 0.008) ( Figure 1B ). The FE NGAL/FE Prot ratio was the best parameter to discriminate the groups, also allowing the differentiation between the ALN group, who exhibited the lowest rates ( Figure 1C ) and the group in PR.
ROC curves for uNGAL, sNGAL and FE NGAL/FE protein ratio were also calculated to discriminate SLE patients with ALN from those with non-renal flare ( Figure 1D ), inactive SLE ( Figure 1E ), or previous renal involvement now in CR ( Figure 1F ). The FE NGAL/FE protein ratio also demonstrated the best ROC profile in all conditions.
When we studied correlations of NGAL with other parameters, a weak correlation between sNGAL and uNGAL levels was found, as shown by the low degree of Spearman's correlation (r = 0.2062, P = 0.0021). Levels of uNGAL also correlated with other renal parameters such as serum creatinine, Upro:Ucr ratio and rSLEDAIs and were inversely correlated with the FE NGAL/FE protein ratio (P < 0.0001) (data not shown). The level of uNGAL was the only parameter correlated with the activity score (r = 0.35, P < 0.015) at the histological level. No associations with the chronicity score or the different histological types of LN were observed.
NGAL and global disease activity. In the cross-sectional study, uNGAL and FE NGAL/FE protein ratio had a significant association with the global SLEDAI-2Ks (r = 0.34 and r = −0.2336, P < 0.0001 and P = 0.0001, respectively) that was mainly dependent on the renal components of the score, since the correlation was lost when only extra-renal manifestations (eSLEDAIs) were considered (r = 0.04 and r = 0.03, ns, respectively). Globally, the association with sNGAL was also weaker (r = 0.1473, P = 0.0454). Similar results were observed in the longitudinal study (data not shown). No significant association was found between NGAL measurements and serum antidsDNA titres (measured by ELISA) and complement (C3 and C4) levels.
Longitudinal NGAL changes and renal disease course LN course and changes in disease activity. A total of 278 observations of reference time points were available during the follow-up period. The median (Q 1 -Q 3 ) number of visits for patients was 4.00 (2.00-6.00) and the time interval, in months, between visits was 1.00 (1.00-3.00). No patients were lost during the study and they were followed-up for 12 months.
Flare. Thirteen patients (29%) had 15 flares during the follow-up, 10 of them were proteinuric (67%) and 4 nephritic (33%). Overall, prior to flare, it was observed a slight progressive increase in uNGAL levels, already statistically significant 3 Total SLEDAI score was determined by the SLEDAI-2K. Renal SLEDAI is scored on an urinalysis that indicates the presence of proteinuria, haematuria, pyuria and urinary cast, each receiving a score of up four points for a total possible ranging from 0 to 16. Extra-renal SLEDAI is scored based on clinical indicators of systemic disease or disease in other organ systems including: neurological, skin, pulmonary and immunological. BUN, blood urea nitrogen; anti-dsDNA, anti-double-stranded DNA; WBC, white blood cells; Upro : Ucre, urine protein/creatinine ratio; eGFR, estimated glomerular filtration rate. Table 3 ). The FE NGAL/FE protein ratio increased between time -A2 and -A1 to later decreased at flare, but changes did not reach statistical significance. However, when values were analysed according to the flare subtype, a statistical significant increase in the FE NGAL/FE protein ratio was observed between times -A2 and -A1 (3-6 months prior) from 17 (95% CI: 8-36) to 39 (95% CI: 21-74) (P = 0.002) decreasing again at flare time (time A) [13 (95% CI: 7-28) (P = 0.041)]. In proteinuric flares, sNGAL and uNGAL levels displayed the same trend than the one observed for total flares (data not shown). Data were not analysed for nephritic flares due to the small number.
These changes occurred alongside persistently elevated rSLEDAIs over time (Table 3) . As in the cross-sectional study, urinary levels correlated moderately with sNGAL at any given time (r = 0.333 (P < 0.0001), whereas an inverse correlation with the FE NGAL/FE protein ratio (r = −0.457, P < 0.0001) was observed. The properties of NGAL to predict the probability of proteinuric flare are summarized using ROC analysis, with a dichotomized outcome (previous times to renal flare versus to no renal flare). A FE NGAL/FE NGAL protein ratio >14.56 [ROC AUC of 0.6995 (95% CI: 0.508-0.890)] displayed the best predictive profile when compared with traditional biomarkers such as anti-dsDNA antibodies and C3 levels ( Table 4) .
CR. At the end of the study, 18 patients (40%) achieved CR, whereas 20 sustained a PR (44%). Over time, all the patients in CR exhibited a significant progressive increase in the FE NGAL/FE protein ratio that reached its peak at the time of CR (time B) with an ∼4-fold increase in respect to the previous visit. This increase was already noticeable 3 months prior to the achievement of CR [from time -B2 to -B1 (P = 0.012)] (Table 3 ) and associated with a significant improvement in the rSLEDAIs over time. No significant changes were observed in both uNGAL and sNGAL.
The properties of NGAL and FE NGAL/FE protein ratio to predict the probability of CR are summarized using ROC analysis, with a dichotomized outcome ( previous time to CR versus to no CR) ( Table 4 ). The FE NGAL/FE protein ratio values >26.54 [ROC AUC 0.692 (95% CI: 0.566-0.818)] exhibited the highest specificity to predict CR (Table 4) .
The specificity was similar to the anti-dsDNA antibodies measurement, but the FE NGAL/FE protein ratio showed the highest sensitivity and negative predictive value (NPV) to predict CR (Table 4) . When results of FE NGAL/FE protein ratios were combined with the improvement of rSLEDAIs over time, the specificity rose to 91%. For patients with sustained partial remission, as it occurred in the cross-sectional study, the FE NGAL/FE protein ratio remained low through the follow-up [19.62 ± 23.64 (mean ± SD)]. A value <19.72 [ROC AUC 0.649 (95% CI: 0.567-0.732)] showed an 88% sensitivity and 37% specificity for PR.
Progression to CKD. Seven patients (16%) (four females and three males) scored in the SLICC index and progressed to an end-stage renal disease (ESRD) in a median (Q 1 -Q 3 ) time of 15 months . Comparisons between patients that progressed and non-progressors at baseline are shown in Table 5 . Progressor patients had significantly increased levels of serum creatinine, daily proteinuria, and sNGAL levels along with a lower eGFR and FE NGAL/FE protein ratio. Although they also exhibited higher uNGAL levels, these were not of statistical significance.
During the follow-up, those patients also showed persistent higher serum (Figure 2A ) and uNGAL levels along with reduced FE NGAL/FE protein ratios ( Figure 2B ). By multivariate Cox regression analysis, baseline eGFR value was the only independent predictor of CKD progression (P = 0.034). Traditional eGFR showed 100% sensitivity, 79% specificity, Table 2 . Baseline characteristics of the 45 patients with newly diagnosed lupus nephritis included in the prospective study The time express in years. c The total SLEDAI score was determined by the SLEDAI-2K. Renal SLEDAI is scored on a urinalysis that indicates the presence of proteinuria, haematuria, pyuria and urinary cast, each receiving a score of up four points for a total possible ranging from 0 to 16. Extra-renal SLEDAI is scored based on clinical indicators of systemic disease or disease in other organ systems including: neurological, skin, pulmonary and immunological. 47% positive predictive value (PPV) and 100% NPV when compared with sNGAL (100% sensitivity, 78% specificity, 47% PPV, 100% NPV) for the progression of the disease.
Although sNGAL results were not able to improve the value of traditional biomarkers, a significant faster progression to CKD was associated with persistent sNGAL levels >444 ng/mL (P = 0.0001) (Figure 3 ).
D I S C U S S I O N
This study confirms that high uNGAL levels reflect the activity and severity of kidney disease in SLE patients, as already shown in previous cross-sectional studies [10] [11] [12] [13] [14] [15] . The main methodological difference is that in addition to measuring uNGAL and sNGAL levels, we also measured the FE NGAL/ FE protein ratio. This is the first time this measurement has been shown to be a good biomarker for active renal disease. In the cross-sectional study, patients with ALN showed significantly reduced FE NGAL/FE protein ratios, mirroring the uNGAL levels, and this measurement exhibited the best specificity and sensitivity to distinguish these patients from those with non-renal disease and from those with a previous history of treated renal involvement that remained in partial remission. Among patients with LN, the uNGAL level was the only parameter that correlated significantly with the urine proteinto-creatinine ratio and the activity score of renal biopsies. No correlations with the biopsy chronicity index were found. These results differ from those of Brunner et al. [29] that found uNGAL levels to be much lower in those with cellular crescents and the combination of NGAL with GFR and MCP1 to be good diagnostic tests of LN chronicity. Whether the uNGAL levels can differentiate histological classes of nephritis remains to be clarified. Only Suzuki et al. [12] in a cohort of paediatric SLE patients was able to show an association with diffuse proliferative glomerulonephritis. None of our measurements allowed us to distinguish between the different histological types of glomerulonephritis. Nevertheless, our study did not have the statistical power to answer this question in view of the small number of patients with type V nephritis included. As previously described, none of the evaluated parameters correlated with the extra-renal disease activity scores or the conventional lupus markers such anti-dsDNA.
Longitudinal data from previous prospective studies have also confirmed uNGAL levels as a significant predictor of renal disease activity in SLE patients and of renal flare in those with a history of biopsy-proven nephritis [11] [12] [13] . Hinze et al.
[11] demonstrated a significant increase in uNGAL/creatinine levels of up to 104% detectable already up to 3 months before worsening of LN, as measured by three standard disease activity indices. In our study, increments of FE NGAL/FE protein ratios, also noticeable 3 months prior to the visit, alongside a concomitant worsening in the rSLEDAIs over time, proved to be the best biomarker to predict flare, mainly of the proteinuric subtype. FE NGAL/FE ratios >14.56 exhibited the best sensitivity (87%) and specificity (62%) even when compared with traditional biomarkers such anti-dsDNA antibodies and C3 levels. The FE NGAL/FE protein ratio along with the renal SLEDAI may be a good tool for monitoring patients with LN. Increments may detect early patients at risk of developing a renal flare and this might prompt early changes in treatment. Less clear is the value of sNGAL as a predictor of renal flare since results are contradictory. Whereas Hinze et al. [11] observed a significant 26% increment in sNGAL levels as early as 3 months before worsening of global and renal SLE disease activity, in Suzuki et al. [12] and in our study, this increase occurred to a much lower degree and was not statistically significant. Not only FE NGAL/FE protein ratio was a good predictor of renal flare but also of remission following treatment. Achievement of CR was characterized by an increment, at least 3 months prior, in uNGAL levels and FE NGAL/FE protein ratios. The significant difference between those patients developing a renal flare and those achieving CR was the simultaneous improvement in the renal disease activity scores in the second group. To our knowledge, this is the first study in patients to show the ability of NGAL to predict recovery. As it occurs in ALN, the source of the peak of NGAL previous to CR is not well understood and a systemic production in addition to local synthesis cannot be excluded. The exact mechanism involved in this dual pro-or anti-reparative effect of NGAL is not clearly elucidated yet, but several hypotheses related to its iron-binding properties [19, 30] , as well as the presence of a different inflammatory renal cytokine milieu and its effect on the expression in both NGAL and its receptor [31] have been proposed to explain the recovery effect. Since this is the only study showing a predictive value of a clinical response, further prospective studies in independent larger cohorts are required to validate our results.
Our results also confirm persistent raised sNGAL levels during the follow-up as a predictor of progression to CKD. The ability to predict progression to an ESRD early in the course of LN is essential. Although hypertension, proteinuria, hyperlidaemia and inflammation represent some important modifiable risk factors, by themselves these elements are not sufficient to properly explain renal outcomes in patients affected by CKD [32] and, currently with the exception of baseline eGFR, no good predictors of progression are available. Recent observations have pointed out the crucial role of the renal tubule and the tubular proteins, such as NGAL, in the genesis and progression of CKD since its release from renal tubule occurs soon after damage, notably preceding the rise in serum creatinine [33] .
Several reports, mainly in diabetic patients with membranous nephropathy, have shown NGAL (urine and serum) levels to be an independent and sensitive renal predictor of CKD [14, 16, 18, 34] . In our cohort, seven (16%) patients progressed to CKD. Although this was a small number, as described previously, eGFR was found to be the only independent prognostic marker of disease progression but higher persistent levels of sNGAL (>444.4 ng/mL) predicted a faster progression. In view of the inverse and direct correlation of Table 4 . Sensitivity, specificity, positive and negative predictive values of the predicted probability of proteinuric flare and CR for serum and normalized uNGAL, FE NGAL/FE protein (%) and anti-dsDNA antibodies 
O R I G I N A L A R T I C L E
N G A L a s a b i o m a r k e r o f L N eGFR with both sNGAL levels and FE NGAL/FE protein ratio, respectively, this molecule may also represent a surrogate index of residual renal function [14, 16] . The main strengths of our study include the simultaneous description of a cross-sectional and a longitudinal study with a large number of participants and outcome events in both, the homogeneity of the study (which may reduce bias), the lack of patients dropping during the follow-up and the available information on a large number of potential confounding factors. However, several limitations should also be considered when interpreting our results. The main one is the impossibility to correlate the NGAL results during the time of disease evolution with the renal histology given the invasive nature of the renal biopsy. Second, the fact that it was a single-centre study and in the longitudinal study we had a relatively short period of follow-up and a limited number of patients developing some of the outcomes such as progression to CKD. However, the different outcomes were reached, and the statistical model was powerful enough to establish independent relationships between NGAL and the clinical outcomes. Third, mainly Caucasian patients treated with MMF as inductionmaintenance therapy were included and different results in other ethnic backgrounds or even under other inductionmaintenance regimens cannot be excluded and require multicentre studies to validate the results. However, no differences in patients from Hispanic and African American origin have been reported previously [14] . Fourth, we have used the no validated rSLEDAI-2Ks as an alternative external standard for the assessment of LN, since the gold standard kidney biopsy cannot be performed serially due to its invasive nature.
In summary, these results confirm that the measurement of the FE NGAL/FE protein ratio provides additional benefit to the traditional biomarkers to stratify the different outcomes of patients with LN. The FE NGAL/FE protein ratio was found to be an excellent candidate to predict a proteinuric flare in the presence of a worsening rSLEDAIs and CR in the presence of a simultaneous improvement. Progression to CKD was best predicted by persistently high levels of sNGAL during the follow-up. These results confirm the potential usefulness of NGAL measurements as a biomarker in LN and may represent a potential target for therapeutic interventions.
Key messages
• The FE NGAL/FE protein ratio is a reliable marker of disease activity in patients with LN and could be used as an indicator of response to therapy.
• Faster progression to CKD in patients with LN was best predicted by persistently high levels of sNGAL during follow-up.
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F I G U R E 2 : Serum NGAL (A) levels and FE NGAL/FE Protein ratio (B) measurements obtained at various time points of the follow-up study. Progressors defined as doubled baseline creatinine levels and/ or progressed to an end-stage renal disease. Values are mean ± SEM . *P < 0.005, **P < 0.0005 comparing progressors versus non-progressors groups.
F I G U R E 3 : Kaplan-Meier survival curves of renal endpoint in patients with serum neutrophil gelatinase-associated lipocalin (sNGAL) levels above and below the optimal receiver operating characteristics cut-off level 444 ng/mL. Patients with sNGAL >444 ng/mL showed a significantly faster progression to endpoint (P = 0.0001, long-rank test).
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